Episode Details

Back to Episodes
First Human ER-100 Results: Did Epigenetic Reprogramming Actually Restore Some Vision in Glaucoma?

First Human ER-100 Results: Did Epigenetic Reprogramming Actually Restore Some Vision in Glaucoma?

Published 1 month ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/first-human-er-100-results-did-epigenetic-reprogramming-actually-restore-some-vision-in-glaucoma

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

First Human ER-100 Results: Did Epigenetic Reprogramming Actually Restore Some Vision in Glaucoma? Evidence cutoff: October 12, 2026. Bottom line Life Biosciences has reported an intriguing first human visual-field signal, but it has not shown that ER-100 restored lost vision. The company says that two of three people with open-angle glaucoma had more than a 4-decibel improvement at at least 28% of visual-field test locations at Day 56. On the registered test pattern, that is about 15 locations. That is worth investigating. But the public report does not include the patients’ visual-field charts, their baseline measurements, repeat-test confirmation, global visual-field scores, or results from the untreated eyes. It also does not establish that the improvement occurred in previously damaged areas or that it reflects retinal ganglion-cell recovery rather than visual-field variability, learning, or another measurement effect. ER-100 may be the first reported human signal for this partial-reprogramming approach. It is not the first human suggestion that some glaucomatous visual dysfunction can improve: earlier studies have reported improved retinal or visual-field measures after pressure reduction and other interventions. Nor do the three ER-100 cases establish that this particular treatment reversed damage. For the full table, please open this article on visualfieldtest.com. The main clinical facts come from Life Biosciences’ October 8 announcement and the trial registry. The company’s release reports the visual-field threshold; the registry describes the trial’s design and planned measurements. () What was actually disclosed Treatment and follow-up The October 8, 2026 announcement concerned three participants with open-angle glaucoma who received one intravitreal injection of ER-100 at Dose Level 1: 2 × 10¹¹ vector genomes in one eye. They took daily oral doxycycline for 56 days to induce expression of OCT4, SOX2, and KLF4, known together as OSK. The company also reported an oral prednisolone taper intended to reduce inflammation related to the adeno-associated virus type 2 vector. It did not disclose the steroid dose or taper schedule in the release. () The company said that visual-field improvement was observed in two of the three participants at Day 56. In both, at least 28% of visual-field locations showed an improvement of more than 4 decibels. The Data Safety Monitoring Board recommended moving to Dose Level 2, 6 × 10¹¹ vector genomes—three times the first dose. () The trial is open-label, non-randomized, and primarily designed to evaluate safety and tolerability. Its registry describes sequential dose escalation in glaucoma, followed by a separate cohort with non-arteritic anterior ischemic optic neuropathy. The full study is planned to follow participants for as long as five years. () What I could verify about the presentation and reporting Life Biosciences announced that it would present the results at Eyecelerator during the American Academy of Ophthalmology meeting. The event listing confirms the October 8 Eyecelerator program. As of October 12, the material I could verify that gives detailed human results is the company’s release; I could not locate a publicly accessible patient-level slide deck, visual-field printouts, presentation transcript, or deta

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us